ASPAVELI

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
II/0028	Update of section 4.8 of the SmPC in order to add urticaria/hives to the list of adverse drug reactions (ADRs) with frequency "common" based on post-marketing data and literature; the Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted.	08/05/2025		SmPC and PL	SmPC new text Table 1 Section 4.8 Frequency of urticaria is reclassified from unknown to common. For more information, please refer to the Summary of Product Characteristics.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
IB/0027	B.II.z - Quality change - Finished product - Other variation	13/11/2024	n/a		
IAIN/0026	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	14/10/2024		Annex II and PL	
IB/0025	B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation	10/10/2024	n/a		
IB/0023	B.I.z - Quality change - Active substance - Other variation	05/09/2024	n/a		
II/0018	Submission of an updated RMP version 2.2 in order to revise the category 3 PASS Sobi.PEGCET-301 and Sobi.PEGCET-302. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	05/09/2024	n/a		

PSUSA/10974 /202311	Periodic Safety Update EU Single assessment - pegcetacoplan	27/06/2024	30/08/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10974/202311.
IB/0022	B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data	16/07/2024		SmPC	
IB/0021/G	This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	02/07/2024	n/a		
II/0011	Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for ASPAVELI, based on final results from study APL2-308. This is a Phase III, randomized, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	25/01/2024	06/05/2024	SmPC and PL	Please refer to Scientific Discussion: Aspaveli-H-C-005553-II-0011.

IB/0020/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	24/04/2024	n/a		
IB/0019/G	This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	05/04/2024	30/08/2024	SmPC	
IB/0016/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of	15/03/2024	n/a		

	manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits				
II/0015	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	14/03/2024	n/a		
PSUSA/10974 /202305	Periodic Safety Update EU Single assessment - pegcetacoplan	30/11/2023	n/a		PRAC Recommendation - maintenance
IB/0013	B.II.z - Quality change - Finished product - Other variation	31/10/2023	n/a		
IB/0014	B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits	13/10/2023	n/a		
PSUSA/10974 /202211	Periodic Safety Update EU Single assessment - pegcetacoplan	08/06/2023	n/a		PRAC Recommendation - maintenance
IB/0009	B.I.z - Quality change - Active substance - Other variation	04/01/2023	n/a		
IB/0007	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	20/12/2022	n/a		

IA/0008/G	This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	15/12/2022	n/a		
PSUSA/10974 /202205	Periodic Safety Update EU Single assessment - pegcetacoplan	01/12/2022	n/a		PRAC Recommendation - maintenance
IA/0006/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test	30/08/2022	n/a		

	procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IA/0005	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	30/08/2022	n/a		
II/0002	Update of sections 4.2, 4.8, 5.1, 5.2 of the SmPC based on final results from study APL2-302 (Pegasus) listed as a category 3 study in the RMP; this is a global, Phase 3, prospective, randomised, multicentre, open-label, active-comparator–controlled study in 80 subjects. The objective was to confirm treatment efficacy and safety of pegcetacoplan monotherapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The submission of this study addresses MEA 001. The Package Leaflet is updated accordingly. The RMP version 1.0 has been agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	19/05/2022	15/02/2023	SmPC and PL	Update of sections 4.4, 4.8, 5.1, 5.2 of the SmPC to reflect efficacy and safety results from the final study APL2-302, including the 48 weeks data. Results of the key efficacy analyses of (OLP) confirm the results observed during the 16-week randomized completion phase (RCP) and suggest an improvement in Paroxysmal Nocturnal Hemoglobinuria (PNH) markers. The PK analysis within OLP showed that therapeutic concentrations of pegcetacoplan were maintained for up to Week 48. The Package Leaflet (PL) was updated accordingly. For more information, please refer to the Summary of Product Characteristics.
IB/0003	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	21/02/2022	15/02/2023	SmPC	
IAIN/0001	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging	20/12/2021	n/a		

	site				